香橼资本：临床试验被FDA搁置 下调Inovio目标价至2美元
© Reuters. 香橼资本：临床试验被FDA搁置 下调Inovio(INO.US)目标价至2美元
智通财经APP获悉，香橼资本将疫苗公司Inovio Pharmaceuticals Inc (NASDAQ:INO) 目标价下调至2美元。
此前FDA叫停Inovio公司COVID-19疫苗INO-4800的II/III期临床试验，表示对试验内容存在"额外的问题"，包括"其Cellectra 2000递送装置将用于试验”所带来的后续问题等。
香橼资本表示，在临床试验被FDA搁置后，Inovio难以获得信任，下调其目标价至2美元。
香橼资本告诉投资者，不但该公司的COVID-19疫苗技术(Cellectra 2000 递送装置)让人质疑，而且很重要的一点是，该公司仍未实现产品转化和获批上市。
截至美股收盘，Inovio收跌6.84%，报11.03美元，盘后续跌超2%。
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.